Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 16 February 2016 | By Zachary Brennan
The US Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) met Tuesday to discuss updates of research programs in the Office of Cellular, Tissue and Gene Therapy (CTGT), which is part of FDA’s Center for Biologics Evaluation and Research (CBER).
The research updates came as Raj Puri, MD, PhD, Director, Division of Cellular, and Gene Therapies (DCGT) at CBER told the committee that although his division has only licensed 12 products in its entire history, more than 1,530 active investigational new drugs (INDs), investigational device exemptions (IDEs) and master files are currently under review, and 106 of those INDs deal specifically with natural killer cells, which play a role in the rejection of tumors and virally-infected cells.
When asked how he plans to deal with what will likely be a backlog of applications, Puri said his division is working to meet 100% of the timelines outlined in the Prescription Drug User Fee Act (PDUFA), which requires payments from industry in exchange for an understanding of how long it will take for an FDA review (typically 10 months, though expedited reviews are six months).
He also said his division continues to plead for additional monetary and staffing resources to meet those challenges.
As far as research priorities, Puri said the division works with virology, immunology, cell and development biology, cancer biology and immunology, biotechnology (genomics, flow cytometry, proteomics) and microbiology of tissue safety:
Puri also said his division is seeing a lot of research around multipotent stromal cells right now:
Carolyn Wilson, PhD, associate director for research at CBER, explained to the committee that the center doesn’t always have the science and methodology to address new gene and cell therapies, though she’s hopeful the advisory committee may help fill some of those gaps.
She also discussed how about 20% of CBER staff are currently working as researchers/regulators, meaning they participate in advisory committees, work on policy documents, help with company inspections, work on external research and attend conferences to put them in “a unique spot to see what’s coming down the pipeline and look to classes of products to identify scientific gaps to ensure research is being used most efficiently.”
Steven Bauer, PhD, Chief of the Cellular and Tissue Therapy Branch at CBER also discussed his branch’s research on cell therapies, stem cells, adult cells and combination products, as well as gene therapies, and diagnostics and cell purification systems.
Following the open discussion and no comments during the public hearing, the advisory committee began its closed portion of the meeting, which is confidential.
Tags: cell and gene therapies, Cellular, Tissue and Gene Therapies Advisory Committee, FDA advisory committee
Regulatory Focus newsletters
All the biggest regulatory news and happenings.